This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Osteoporosis	IL-20	<p><i>In vitro</i> and mouse studies suggest IL-20 inhibitors could help treat osteoporosis. In osteoporosis patients and mice, serum levels of IL-20 were higher than those in healthy controls. In the same mice, an anti-IL-20 antibody decreased bone loss and increased bone mineral density compared with a control antibody. A forthcoming publication will show that the anti-IL-20 antibody decreased bone metastases in animal models of cancer.</p> <p>Novo Nordisk A/S has an anti-IL-20 antibody in Phase II testing to treat rheumatoid arthritis (RA).</p> <p>SciBX 4(33); doi:10.1038/scibx.2011.940 Published online Aug. 25, 2011</p>	Patented by the National Cheng Kung University; available for licensing or partnering	<p>Hsu, Y.-H. <i>et al. J. Exp. Med.</i>; published online Aug. 15, 2011; doi:10.1084/jem.20102234</p> <p>Contact: Ming-Shi Chang, National Cheng Kung University, Tainan City, Taiwan e-mail: mschang@mail.ncku.edu.tw</p>